February 28th 2024
In a discussion with Targeted Oncology, Michael Gibson, MD, PhD, discusses the benefits of using a patient’s PD-L1 combined positive score to determine if they are given nivolumab and chemotherapy to treat their gastric cancer.
November 16th 2023
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Ramucirumab/Durvalumab Combo Produces Antitumor Activity in Gastric, GEJ Cancer
January 25th 2018According to findings presented at the 2018 Gastrointestinal Cancers Symposium, the combination of the VEGFR-2 inhibitor ramucirumab (Cyramza) plus the anti–PD-L1 agent durvalumab (Imfinzi) demonstrated antitumor activity in a phase Ia/b study of patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
Read More
Avelumab Fails to Improve OS in Phase III Gastric Cancer Trial
November 30th 2017In findings from the phase III JAVELIN Gastric 300 trial, survival was not improved with the anti–PD-L1 agent avelumab compared with chemotherapy in previously treated patients with gastric or gastroesophageal junction adenocarcinoma.<br />
Read More
Pembrolizumab Receives FDA Approval for PD-L1+ Gastric Cancer
September 23rd 2017Based on findings from the phase II KEYNOTE-059 study, pembrolizumab has been granted FDA approval for the treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have received 2 or more lines of chemotherapy, including fluoropyrimidine- and platinum-containing chemotherapy, and, if appropriate, HER2/neu-targeted therapy.
Read More
Efficacy and Safety Results for Pembrolizumab in Previously Treated Gastric Cancer
June 13th 2017Charles S. Fuchs, MD, MPH, professor of Medicine, director, Yale Cancer Center, and physician-in-chief, Smilow Cancer Hospital, discusses efficacy and safety results for pembrolizumab (Keytruda) monotherapy in patients with previously treated advanced gastric cancer.
Watch
In updated findings from the KEYNOTE-059 trial of pembrolizumab in advanced gastric or gastroesophageal junction (GEJ) cancer, the PD-1 inhibitor maintained signs of its clinical benefit in this patient population, which is encouraging as the indication is currently under consideration for approval with the FDA.
Read More
Pembrolizumab Granted Priority Review by the FDA for Advanced Gastric Cancer
May 25th 2017Pembrolizumab (Keytruda) has been granted a priority review by the FDA for the treatment of patients who have undergone at least 2 courses of chemotherapy for recurrent or advanced gastric or gastroesophageal junction adenocarcinoma.
Read More